Loading stock data…
Enliven Therapeutics (ELVN)
$50.85+0.77 (+1.54%)
After Hours$51.00+0.15 (+0.29%)· Last close Jun 29
Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Enliven Therapeutics, Inc. in the Healthcare sector is trading at $50.85 with a market capitalization of $2.9B. Wall Street consensus targets $62.89 (9 analysts), implying a +23.7% move over the next 12 months. The stock is currently near its 52-week high of $51.05, remaining 74.8% above its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the safe zone. The Whystock Score of 90/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +23.7% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$27.82M↑ | -$34.28M↓ | -$25.10M↑ | -$28.58M↑ | -$31.69M |
| Net Income | -$23.63M↑ | -$29.67M↓ | -$20.15M↑ | -$25.34M↑ | -$28.54M |
Peer Comparison
JNJUNHPFE
Fundamentals
Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. Its clinical programs comprise ELVN-001, a small molecule kinase inhibitor whi...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$2.93B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-21.79%
Volume
Today's trading volume
1.54M
Recent News
What to Know About This $345,000 Enliven Insider Sale as the Stock Soars 130%
This Boulder biotech advancing cancer drugs saw a notable insider sale amid strong 1-year stock gains and early clinical progress.
What to Know About OrbiMed's $39 Million Enliven Therapeutics Stock Sale Amid a 130% Rally
Focused on cancer therapies, this Boulder-based biotech reported significant insider selling amid a year of sharp share price gains.
Medical Hedge Fund Sells 281,000 Shares of Enliven Theapeutics. Is it Time to Sell ELVN?
This clinical-stage biotech advancing cancer therapies reported a notable insider sale as its lead candidates progress in early trials.
Enliven Therapeutics (ELVN) Soars on Stellar Leukemia Drug Trial
Enliven Therapeutics Inc. (NASDAQ:ELVN) is one of the 10 Stocks That Absolutely Exploded Higher. Enliven Therapeutics rallied for a fourth consecutive day on Friday, climbing 14.30 percent to finish at $46.13 apiece, as investor sentiment was bolstered by the encouraging results from its experimental leukemia drug, ELVN-001. In an updated report, Enliven Therapeutics Inc. (NASDAQ:ELVN) […]
ELVN Stock On Track For Best Week Since March Following FDA-Aligned Path For Cancer Drug Development
As of March 2026, ELVN-001 produced meaningful responses in heavily pretreated patients, many of whom had already tried multiple existing therapies, Enliven Therapeutics said.